• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450

Introduction to (6-Chloro-4-(trifluoromethyl)pyridin-2-yl)boronic Acid (CAS No. 1217500-88-3)

(6-Chloro-4-(trifluoromethyl)pyridin-2-yl)boronic acid is a highly specialized organoboron compound that has garnered significant attention in the field of pharmaceutical and chemical research. This compound, identified by its CAS number CAS No. 1217500-88-3, is a key intermediate in the synthesis of various biologically active molecules. Its unique structural features, including the presence of both chloro and trifluoromethyl substituents on a pyridine ring, make it a versatile building block for the development of novel therapeutic agents.

The significance of this compound lies in its utility as a precursor in cross-coupling reactions, particularly in Suzuki-Miyaura couplings, which are fundamental in constructing complex organic molecules. The boronic acid functional group at the 2-position of the pyridine ring enhances its reactivity, allowing for efficient coupling with aryl halides or other boronic acids under palladium catalysis. This reaction is widely employed in the pharmaceutical industry to create diverse and intricate molecular architectures.

Recent advancements in medicinal chemistry have highlighted the importance of heterocyclic compounds in drug design. Pyridine derivatives, such as (6-chloro-4-(trifluoromethyl)pyridin-2-yl)boronic acid, are particularly valuable due to their ability to modulate biological pathways effectively. The trifluoromethyl group, a common pharmacophore, is known to enhance metabolic stability and binding affinity to biological targets. Similarly, the chloro substituent can serve as a handle for further functionalization, enabling chemists to tailor the properties of the final drug candidates.

In the context of modern drug discovery, (6-chloro-4-(trifluoromethyl)pyridin-2-yl)boronic acid has been utilized in the synthesis of small-molecule inhibitors targeting various diseases. For instance, studies have demonstrated its role in developing kinase inhibitors, which are crucial for treating cancers and inflammatory disorders. The ability to precisely modify the pyridine core allows researchers to optimize potency and selectivity, thereby minimizing off-target effects.

The compound's reactivity also makes it an attractive candidate for material science applications. Boronic acids are known for their ability to form covalent bonds under mild conditions, making them suitable for creating advanced materials such as polymers and coatings. The incorporation of (6-chloro-4-(trifluoromethyl)pyridin-2-yl)boronic acid into these materials can impart unique properties, such as enhanced durability or biocompatibility.

From a synthetic chemistry perspective, (6-chloro-4-(trifluoromethyl)pyridin-2-yl)boronic acid exemplifies the power of transition metal-catalyzed reactions in organic synthesis. The Suzuki-Miyaura coupling reaction, in particular, has revolutionized the way complex molecules are constructed. By leveraging this reaction, chemists can efficiently build intricate structures that would be otherwise challenging to achieve through traditional synthetic methods.

The growing interest in fluorinated compounds underscores their prevalence in modern pharmaceuticals. The trifluoromethyl group, present in (6-chloro-4-(trifluoromethyl)pyridin-2-yl)boronic acid, is one such fluorinated moiety that has been extensively studied for its pharmacological benefits. Its electron-withdrawing nature increases lipophilicity and bioavailability, while also improving resistance to metabolic degradation. These attributes make it an indispensable component in drug design.

Furthermore, the chloro substituent on the pyridine ring offers additional synthetic flexibility. It can be readily transformed into other functional groups through nucleophilic aromatic substitution or metal-halogen exchange reactions. This adaptability allows researchers to explore diverse chemical space and discover novel therapeutic entities with tailored properties.

The application of computational methods has further enhanced the utility of (6-chloro-4-(trifluoromethyl)pyridin-2-yl)boronic acid in drug discovery. Molecular modeling techniques enable researchers to predict how this compound will interact with biological targets at the atomic level. This information is crucial for designing optimized drug candidates with improved efficacy and safety profiles.

In conclusion, (6-chloro-4-(trifluoromethyl)pyridin-2-yl)boronic acid is a multifaceted compound with significant implications in pharmaceutical and material science research. Its unique structural features and reactivity make it a valuable tool for constructing biologically active molecules and advanced materials. As research continues to evolve, this compound will undoubtedly play an increasingly important role in addressing some of today's most pressing scientific challenges.

• 870459-90-8((4-(Trifluoromethyl)pyridin-2-yl)boronic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)